Low impact
Eli Lilly is suing pharmacies and peptide vendors over the unauthorized sale of compounded versions of its weight-loss drug retatrutide.
MarketWatch08/12, 08:07 PM
Related assets
Coming up for LLY
Explore next
Latest LLY news
Jin1008/17, 07:48 PM
Bloomberg08/13, 05:57 PM
FirstSquawk08/13, 12:08 PM
Berenberg raises Eli Lilly price target to $1,220 from $1,135.